X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of X4 Pharmaceuticals, Inc. Common Stock on an amended Schedule 13G. The Master Fund directly holds 7,933,491 shares of Common Stock and 151,515 Warrants that are immediately exercisable, for an aggregate of 8,085,006 shares deemed beneficially owned.
Based on 99,146,743 shares of Common Stock outstanding as of July 31, 2026, each Reporting Person’s beneficial ownership is 8.1%. All 8,085,006 shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive power. The Warrants are subject to a 9.99% Beneficial Ownership Limitation.
Deep Track Capital and affiliates report beneficial ownership of X4 Pharmaceuticals common stock and related securities as of June 30, 2026. The group collectively reports 8,040,894 shares beneficially owned, representing 8.33% of the common stock, all with shared voting and dispositive power.
This position includes 2,162,137 Pre-Funded Warrants exercisable into common stock, subject to a 9.99% "Maximum Percentage" ownership cap that limits exercises if they would push holdings above that threshold. Ownership percentages are based on 96,481,833 shares, including 94,319,696 shares outstanding as of May 1, 2026 plus the shares issuable upon warrant exercise within the cap.
X4 Pharmaceuticals, Inc. president John Volpone reported selling 24,576 shares of common stock on August 12, 2026 at a weighted average price of $4.44 per share, in transactions ranging from $4.33–$4.55, to cover a personal income tax obligation upon settlement of a restricted stock unit award. Following these sales, he directly holds 265,305 shares, of which 193,254 shares represent restricted stock units.
X4 Pharmaceuticals, Inc. Executive Chairman Adam R. Craig reported selling 47,436 shares of common stock on August 12, 2026 in an open-market transaction at a weighted average price of $4.4445 per share, with individual trade prices ranging from $4.33 to $4.55. According to the disclosure, the sale was made to cover personal income tax obligations arising from the settlement of a restricted stock unit award. Following this transaction, Craig directly held 328,651 shares of common stock, including 193,254 shares represented by restricted stock units.
X4 Pharmaceuticals, a biopharma focused on rare hematology diseases, reported Q2 2026 revenue of $8.8 million, up from $2.0 million a year earlier, driven by license and other revenue from its Norgine partnership and higher net product sales of XOLREMDI, which reached $2.4 million. Net loss narrowed to $16.2 million from $25.7 million as research and development and general and administrative expenses declined following 2025 restructuring actions.
As of June 30, 2026, cash, cash equivalents and short‑term marketable securities totaled $208.0 million, with $40.4 million used in operating activities in the first half of 2026. Long‑term financing is anchored by the Hercules Loan Agreement, with $75.0 million of principal outstanding and total principal plus end‑of‑term payments of $77.0 million due July 1, 2027. Management expects current liquidity to fund operations and debt obligations for at least the next 12 months, while continuing to anticipate operating losses and the need to raise additional capital over time.
XOLREMDI has accelerated approval in the United States for WHIM syndrome and obtained European Commission marketing authorization in April 2026, with commercialization in Europe out‑licensed to Norgine and the approved MAA transferred in July 2026. The pivotal 4WARD Phase 3 trial in chronic neutropenia is ongoing under a new CRO, with an FDA meeting planned to revisit sample size and an enrollment update targeted by the end of the third quarter.
BlackRock, Inc. reports beneficial ownership of common stock of X4 PHARMACEUTICALS INC. BlackRock holds 5,529,573 shares, representing 5.9% of the outstanding common stock. It has sole voting powersole dispositive power
Various underlying clients and accounts have rights to dividends and sale proceeds from these shares, but no single underlying interest exceeds five percent of X4 PHARMACEUTICALS INC’s total outstanding common stock.
X4 Pharmaceuticals Chief Financial Officer David Kirske sold 8,543 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $4.2641 per share, in multiple trades between $4.21 and $4.31.
According to the filing, the sale was made to cover a personal income tax obligation arising from the settlement of a restricted stock unit award. After this transaction, Kirske directly owns 167,750 shares of X4 Pharmaceuticals common stock, including 96,627 shares represented by restricted stock units.
X4 Pharmaceuticals director Kelly Gold received a stock option grant as part of compensation. The award covers 110,000 shares of common stock with an exercise price of $4.085 per share and expires on July 1, 2036. According to the disclosure, these options were granted at no cost on the grant date and will vest in full on the one-year anniversary of the grant date, as long as Gold continues providing services through that date. Following this award, Gold is reported to hold stock options covering 110,000 shares directly.